LEAPS Collaboration to Create First Genetic Map of Parkinson's Disease
The Michael J. Fox Foundation for Parkinsonís Research (MJFF) announced that the first award under its Linked Efforts to Accelerate Parkinsonís Solutions (LEAPS) program will aim to create the first whole genome study, or genetic map, of Parkinsonís disease within one year. The collaboration brings together Mayo Clinicís patient database and Perlegen Sciencesí high-density array genotyping technology.
Project funding will total approximately $2.8 million, assuming all milestones are met.† Funding was made possible by a lead grant from prominent
ďWe are excited to serve as a catalyst for the first genetic map of Parkinsonís disease,Ē said
The team, led by coordinating investigator David R.Cox, MD, PhD, chief scientific officer of Perlegen, and
Perlegen is currently collaborating with Pfizer Inc. to discover genetic markers for metabolic syndrome and test drug response for major depression, with AstraZeneca to discover gene variants that predispose patients to heart attack, and with Lilly and Bristol Myers Squibb, among others, to use whole genome studies to determine drug response. Parkinsonís disease was not a focus prior to this collaboration, and this project would not have occurred without funding from The Michael J. Fox Foundation.